Allspring Global Investments Holdings LLC Sells 10,199 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Allspring Global Investments Holdings LLC trimmed its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 42.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,064 shares of the company's stock after selling 10,199 shares during the period. Allspring Global Investments Holdings LLC's holdings in Amphastar Pharmaceuticals were worth $511,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of AMPH. Pacer Advisors Inc. increased its position in Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares during the period. Boston Trust Walden Corp boosted its stake in shares of Amphastar Pharmaceuticals by 81.4% in the 4th quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after purchasing an additional 439,281 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Amphastar Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock worth $44,674,000 after buying an additional 14,015 shares during the period. Portolan Capital Management LLC lifted its holdings in Amphastar Pharmaceuticals by 201.1% in the third quarter. Portolan Capital Management LLC now owns 327,764 shares of the company's stock valued at $15,906,000 after buying an additional 218,901 shares during the period. Finally, Nordea Investment Management AB raised its position in shares of Amphastar Pharmaceuticals by 4.8% during the 4th quarter. Nordea Investment Management AB now owns 279,714 shares of the company's stock valued at $10,386,000 after acquiring an additional 12,851 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on AMPH shares. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 target price for the company. StockNews.com cut shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Finally, Piper Sandler lowered shares of Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $66.00 to $36.00 in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $50.33.

Insider Activity at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 10,000 shares of the firm's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the transaction, the director now owns 30,471 shares of the company's stock, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Rong Zhou sold 7,000 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the transaction, the executive vice president now owns 118,469 shares of the company's stock, valued at $5,262,392.98. The trade was a 5.58 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Stock Down 9.7 %

Shares of AMPH traded down $3.06 during midday trading on Friday, hitting $28.43. The stock had a trading volume of 1,792,655 shares, compared to its average volume of 569,790. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 9.48, a price-to-earnings-growth ratio of 2.19 and a beta of 0.81. The company has a 50 day simple moving average of $34.95 and a two-hundred day simple moving average of $42.67. Amphastar Pharmaceuticals, Inc. has a twelve month low of $27.82 and a twelve month high of $53.96.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.